Holding
In
Raytheon Technologies Corp. v. General Electric Co.,
2021 U.S. App. LEXIS 10961 (Fed. Cir., Apr. 16, 2021), the Federal
Circuit (Judges Chen, Lourie, and Hughes) reversed the PTAB s
Final Written Decision that certain challenged claims of
Raytheon s U.S. Patent No. 9,695,751 ( the 751
patent ) would have been unpatentable as obvious. The Federal
Circuit held that the relied-upon prior art failed to enable one of
ordinary skill to make and use the claimed invention.
Background
Raytheon s patent is directed to gas turbine engines and
recites a power density range. The claims
read, in relevant part:
A gas turbine engine comprising:
a fan including a plurality of fan blades . . . ; a compressor
Obhan & Associates
Trademarks Comparative Guide for the jurisdiction of India, check out our comparative guides section to compare across multiple countries
Dennemeyer Group
Though we may not all admit it, few among us can resist the appeal of a candy bar. But did you know the history of these confections and their value as Intellectual Property assets?
Jenner & Block
On April 5, 2021, the US Supreme Court decided the long-running and closely-watched case of Google v. Oracle
Volpe Koenig
Functional claim language which defines an invention by what it does rather than what it is can be a powerful claim drafting tool when used carefully.
Panel: Judges Taranto, Chen, and Stoll, with
Judge Chen writing the opinion
You should read this case if: you want to
better understand the preclusive effect (or lack thereof) of
contingent findings and alternative holdings.
In this week s featured case, the Federal Circuit resolved
an interesting case where a patent-owner appellant appealed a
district court judgment holding its patent claims invalid but asked
the Federal Circuit to affirm invalidity. That perhaps surprising
situation arose because the district court s opinion supporting
its judgment appeared to address multiple invalidity grounds, and
the patent owner was seeking to protect against potential
preclusive effects of some of those grounds. Ultimately, though,
U.S. Patent Office Issues Notice of Allowance for Nicox s Latanoprostene Bunod in Normal Tension Glaucoma
April 27, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA
, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.
To print this article, all you need is to be registered or login on Mondaq.com.
On April 20, 2021, ALJ David P. Shaw issued the public version
(
Part I, Part II, Part III, Part IV, Part V) of his final initial determination
( ID ) finding a violation of section 337 in
Certain
High-Density Fiber Optic Equipment and Components Thereof
(Inv. No. 337-TA-1194).
By way of background, this investigation was based on a February
21, 2020 complaint filed by Corning Optical Communications LLC
( Corning ) alleging violations of section 337 by
thirteen respondents, including Remaing Respondents FS.com Inc.
( FS ), Leviton Manufacturing Co., Inc.
( Leviton ), Panduit Corp. ( Panduit ), The